← Back to Search
Phase I/II RAF Kinase Inhibitors In Cancer Therapy
S. Turajlic, Z. Ali, N. Yousaf, James Larkin
Published 2013 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Introduction: Aberrant activation of RAF signalling is a frequent finding in human cancers. BRAF is the only RAF family member that is commonly mutated, whilst CRAF and ARAF play important roles in the signal transduction from mutant RAS. BRAF-specific inhibitors have been more effective in the treatment of BRAF-mutant melanoma than BRAF-mutant thyroid and colorectal cancers. Areas covered: The review summarises the experience with RAF kinase inhibitors, including efficacy, modes of acquired resistance, and the mechanism behind the progression of pre-malignant RAS-mutant lesions observed with RAF kinase inhibitors. The authors review all the completed and ongoing Phase I or II clinical trials of RAF kinase inhibitors and discuss in detail the rationale behind the combinatorial approaches. Expert opinion: The success of RAF kinase inhibitors has demonstrated the necessity of genotype-driven treatment selection for cancer patients. The spectrum of responses in different tumour types is explained by feedback events that are determined by cell lineage. Dissection of these events and the mechanisms of acquired resistance will determine the appropriate combination therapies. Ongoing characterisation of RAS-MAPK regulation in malignant cells may aid the development of novel agents that have greater potency for the inhibition of activated RAF kinase, and lesser propensity for promotion of RAS-mutant tumours.
This paper references
This paper describes the mechanism by which BRAF mutations activate the MAPK signalling pathway
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
A. Mccullough (2013)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
W. Sharfman (2011)
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).
G. Schwartz (2009)
BRAF mutations in hairy-cell leukemia.
E. Tiacci (2011)
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
S. Kopetz (2010)
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
Targeting RAF: trials and tribulations
J. Downward (2011)
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Z. Dubauskas (2009)
Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.
K. Flaherty (2009)
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
H. Yang (2012)
DHODH modulates transcriptional elongation in the neural crest and melanoma
Richard M. White (2011)
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
Initial genome sequencing and analysis of multiple myeloma
M. A. Chapman (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm (2006)
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
Cristina Montero-Conde (2013)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
A. Prahallad (2012)
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
P. Wan (2004)
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
E. Ellebaek (2012)
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
S. Kopetz (2010)
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
Renal cell carcinoma and the use of sorafenib
James M G Larkin (2006)
Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
P. Mordant (2010)
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
J. P. Arnault (2009)
RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma
Y. Zhang (2010)
PLX4032 in metastatic colorectal cancer patients with BRAF tumors
S Kopetz (2010)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
K. Paraiso (2012)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
BRAF inhibition can induce noncutaneous RAS-mutant cancers
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
Phase II trial of sorafenib in metastatic thyroid cancer.
R. T. Kloos (2009)
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
Gajanan S. Inamdar (2010)
Melanoma brain metastases and vemurafenib: need for further investigation.
N. Rochet (2012)
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
R. Corcoran (2012)
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Rafael B Blasco (2011)
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Y. Su (2012)
Raf proteins and cancer: B-Raf is identified as a mutational target.
K. Mercer (2003)
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
N. Jin (2011)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Victoria Emuss (2005)
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
M. Martin (2012)
Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation
C. Mason (1999)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
J. Chernoff (2011)
Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.
J. Weber (2012)
This was the first paper to describe mutations in BRAF in cancer
Regulation and Role of Raf-1/B-Raf Heterodimerization
L. Rushworth (2006)
C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
F. Karreth (2011)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
J. Sosman (2012)
A comprehensive catalogue of somatic mutations from a human cancer genome
E. Pleasance (2010)
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
P. Oberholzer (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
J. Tsai (2008)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
Mechanisms of regulating the Raf kinase family.
H. Chong (2003)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.
G. Schwartz (2009)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
A. Rebocho (2013)
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and Phase I/II RAF kinase inhibitors in cancer therapy
A Hauschild (2013)
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor
D. Stuart (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A. Hauschild (2012)
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
This paper is referenced by
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
B. Cseh (2014)
The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.
Marzieh Armat (2016)
New RAF kinase inhibitors in cancer therapy
J. Martin-Liberal (2014)
[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models
Tetyana Tegnebratt (2013)
V. Yang (2015)
RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge
G. Maik-Rachline (2018)
Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers.
Ki Hwan Kweon (2014)
One Hippo and many masters: differential regulation of the Hippo pathway in cancer.
D. Romano (2014)
Protein kinase inhibitors: breakthrough medicines and the next generation
T. Sawyer (2013)
N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.
Y. Li (2015)
Targeted Therapies For Intestinal Tumorigenesis
E. Chiorean (2015)